Khatchadourian Christopher, Sisliyan Christina, Nguyen Kevin, Poladian Nicole, Tian Qi, Tamjidi Faraaz, Luong Bao, Singh Manpreet, Robison Jeremiah, Venketaraman Vishwanath
College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Department of Emergency Medicine, St. Barnabas Hospital Health System, Bronx, NY 10457, USA.
Clin Pract. 2021 Sep 22;11(4):694-707. doi: 10.3390/clinpract11040085.
Obesity and hyperlipidemia are known to be risk factors for various pathological disorders, including various forms of infectious respiratory disease, including the current Coronavirus outbreak termed Coronavirus Disease 19 (COVID-19). This review studies the effects of hyperlipidemia and obesity on enhancing the inflammatory response seen in COVID-19 and potential therapeutic pathways related to these processes. In order to better understand the underlying processes of cytokine and chemokine-induced inflammation, we must further investigate the immunomodulatory effects of agents such as Vitamin D and the reduced form of glutathione as adjunctive therapies for COVID-19 disease.
众所周知,肥胖和高脂血症是多种病理疾病的危险因素,包括各种形式的传染性呼吸道疾病,包括当前被称为冠状病毒病19(COVID-19)的冠状病毒爆发。本综述研究了高脂血症和肥胖对增强COVID-19中炎症反应的影响以及与这些过程相关的潜在治疗途径。为了更好地理解细胞因子和趋化因子诱导的炎症的潜在过程,我们必须进一步研究维生素D和还原型谷胱甘肽等药物作为COVID-19疾病辅助治疗的免疫调节作用。